AngioDynamics (ANGO) Hits 52-Week High on Positive View

A generic image of stock metrics
Credit: Shutterstock photo

Shares of AngioDynamics Inc.ANGO reached a 52-week high of $17.32 on Sep 7, 2016, eventually closing slightly lower at $17.26. This represents strong year-to-date returns of about 42.2%. The S&P 500 has returned only about 7.0% during the same period.

Headquartered in Latham, NY, AngioDynamics designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. In July, this Zacks Rank #3 (Hold) stock reported earnings per share of 19 cents for the fourth quarter of fiscal 2016, beating the Zacks Consensus Estimate of 16 cents.

Key Growth Catalysts

The bullish run reflects a positive long-term outlook, an expanding product portfolio, an innovative pipeline and improving operating efficiency. We believe that an expanding portfolio, which includes products like Asclera, AngioVac, BioFlo and NanoKnife, significantly enhances AngioDynamics' market opportunities. The company continues to enjoy healthy demand for the NanoKnife system and received clearance in China during the quarter. Japan also holds huge prospect for the product in the long haul.

AngioDynamics forecasts first-quarter fiscal 2017 sales in the range of $84 million to $87 million. Adjusted earnings are projected in the band of $0.11 to $0.14 per share.

ANGIODYNAMICS Price and Consensus


For full fiscal 2017, AngioDynamics expects sales in the range of $355 million to $360 million. At the mid-point, this range reflects year-over-year growth of 1%. Adjusted earnings are forecast in the range 62 cents to 65 cents per share, reflecting almost 9.5% growth from fiscal 2016.

AngioDynamics expects gross margin of 51% for fiscal 2017, which is slightly better than the fiscal 2016 figure. The company also anticipates an excess of $30 million in cash.

Stocks to Consider

Some better-ranked stocks in the broader medical sector are GW Pharmaceuticals plc GWPH , NuVasive, Inc. NUVA and Quidel Corp. QDEL . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANGIODYNAMICS (ANGO): Free Stock Analysis Report

NUVASIVE INC (NUVA): Free Stock Analysis Report

GW PHARMA-ADR (GWPH): Free Stock Analysis Report

QUIDEL CORP (QDEL): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More